Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) as a novel apoptosis-inducing anticancer agent

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1546-1556

  Narla, Rama Krishna ^a   Dong, Yanhong ^a   D'Cruz, Osmond J ^a   Navara, Christopher ^a   Uckun, Fatih M ^a  

^a PARKER HUGHES INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,10 PHENANTHROLINE; 2,2' BIPYRIDINE DERIVATIVE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACETOPHENONE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATIC COMPOUND; BIS(4,7 DIMETHYL 1,10 PHENANTHROLINE) SULFATOOXOVANADIUM; HETEROCYCLIC COMPOUND; UNCLASSIFIED DRUG; VANADYL DERIVATIVE; VANADYL SULFATE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHELATION; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIGAND BINDING; NICK END LABELING; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL SURVIVAL; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; IN SITU NICK-END LABELING; INHIBITORY CONCENTRATION 50; ORGANOMETALLIC COMPOUNDS; TUMOR CELLS, CULTURED; VANADATES;

EID: 0034005484     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Barceloux, D. G. Vanadium. J. Toxicol. Clin. Toxicol. 37: 265-278, 1999.
2. Macara, I. G. Vanadium: an element in search of a role. Trends Biochem. Sci., 5: 92-94, 1980.
3. Rehder, D. The bioinorganic chemistry of vanadium. Angew Chem. Int. Ed. Engl. 130: 148-167, 1991.
4. Nachay, B. R. Mechanisms of action of vanadium. Annu. Rev. Pharmacol. Toxicol., 24: 501-524, 1982.
5. Abou-Seif, M. A. Oxidative stress of vanadium-mediated oxygen free radical generation stimulated by aluminium on human erythrocytes. Ann. Clin. Biochem., 35: 254-260, 1998.
6. Shi, X., Jiang, H., Mao, Y., Ye, J., and Saffiotti, U. Vanadium(IV)-mediated free radical generation and related 2′-deoxyguanosine hydroxylation and DNA damage. Toxicology 106: 27-38, 1996.
7. El-Naggar, M. M., El-Waseef, A. M., El-Halafawy, K. M., and El-Sayed, I. H. Antitumor activities of vanadium(IV), manganese(IV), iron(III), cobalt(II) and copper(II) complexes of 2-methylaminopyridine. Cancer Lett., 133: 71-76, 1998.
8. Byczkowski, J. Z., Wan, B., and Kulkarni, A. P. Vanadium-mediated lipid peroxidation in microsomes from human term placenta. Bull. Environ. Contam. Toxicol., 41: 696-703, 1988.
9. Ozawa, T., and Hanaki, A. ESR evidence for the formation of hydroxyl radicals during the reaction of vanadyl ions with hydrogen peroxide. Chem. Pharm. Bull., 37: 1407-1409, 1989.
10. Carmichael, A. J. Vanadyl-induced Fenton like reaction in mRNA: an ESR and spin trapping study. FEBS Lett., 261: 165-170, 1990.
11. Kopf-Maier, P. Complexes of metals other than platinum as antitumor agents. Eur. J. Clin. Pharmacol., 47: 1-16, 1994.
12. Moebus, V. J., Stein, R., Kieback, D. G., Runnebaum, I. B., Sass, G., and Kreienber, R. Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives. Anticancer Res., 17: 815-822, 1997.
13. 2 after treatment of Ehrlich ascites tumor cells with metallocene dichlorides and cis-platinum in vitro. Cancer Res. Clin. Oncol., 106: 44-52, 1983.
14. Kopf-Maier, P. Antitumor bis(cyclopentadienyl) metal complexes. In: B. K. Keppler (Ed.), Metal Complexes in Cancer Chemotherapy. New York: VCH Publishers, 259-296, 1993.
15. Sakurai, H., Tamura, H., and Okatami, K. Mechanism for a new antitumor vanadium complex hydroxyl radical-dependent DNA-cleavage by 1,10-phenanthroline-vanadyl complex in the presence of hydrogen peroxide. Biochem. Biophys. Res. Commun., 206: 133-137, 1995.
16. Dong, Y., Narla, R. K., Sudbeck, E., and Uckun, F. M. Synthesis and X-ray structure of oxovanadium(IV) complexes. J. Inorg. Biochem., in press.
17. Uckun, F. M., Evans, W. E., Forsyth, C. J., Waddick, K. G., Tuel-Ahlgren, L., Chelstrom, L. M., Burkhardt, A., Bolen, J., and Myers, D. E. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinase. Science (Washington DC), 267: 886-891, 1995.
18. Waurzyniak, B., Shneider, E. A., Tumer, N., Yanishevski, Y., Gunther, R., Chelstrom, L., Wendorf, H., Myers, D. E., Irvin, J. D., Messinger, Y., Ek, O., Zeren, T., Chandan-Langlie, M., Evans, W. E., and Uckun, F. M. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clin. Cancer Res., 3: 881-890, 1997.
19. Perentesis, J. P., Waddick, K. G., Bendel, A. E., Shao, Y., Warman, B. E., Chandan-Langlie, M., and Uckun, F. M. Induction of apoptosis in multi-drug resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the granulocyte macrophage colony stimulating factor receptor. Clin. Cancer Res., 3: 347-355, 1997.
20. Narla, R. K., Liu, X. P., Myers, D. E., and Uckun, F. M. 4-(3′-Bromo-4′hydroxylphenyl)-amino-6,7-dimethoxyquinazoline, a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Clin. Cancer Res., 4: 1405-1414, 1998.
21. Uckun, F. M., Gajl-Peczalska, K. J., Kersey, J. H., Houston, L. L., and Vallera, D. A. Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. J. Exp. Med., 163: 347-68, 1986.
22. Uckun, F. M., Dibirdik, I., Smith, R., Tuel-Ahlgren, L., Chandan-Langlie, M., Schieven, G. L., Waddick, K. G., Hanson, M., and Ledbetter, J. A. Interleukin 7 receptor ligation stimulates tyrosine phosphorylation, inositol phospholipid turnover, and clonal proliferation of human B-cell precursors. Proc. Natl. Acad. Sci. USA, 88: 3589-3593, 1991.
23. Uckun, F. M., Jaszcz, W., Chandan-Langlie, M., Waddick, K. G., Gajl-Peczalska, K., and Song, C. W., Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia. J. Clin. Invest., 91: 1044-1051, 1993.
24. Zhu, D-M., Narla, R. K., Fang, W., Chia, N., and Uckun, F. M. Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells. Clin. Cancer Res., 4: 2967-2976, 1998.
25. Uckun, F. M., Narla, R. K., Jun, X., Zeren, T., Venkatachalam, T., Waddick, K. G., Rostostev, A., and Myers, D. E. Cytotoxic activity of EGF-genstein against breast cancer cells. Clin. Cancer Res., 4: 901-912, 1998.
26. Djordjevic, C. Antitumor activity of vanadium compounds. In: H. Sigel and A. Sigel (Eds.), Metal Ions in Biological Systems, Vol. 31, pp. 595-616. New York: Marcel Dekker, Inc., 1995.
27. Djordjevic, C., and Wampler, G. L. Antitumor activity and toxicity of peroxo heteroligand vanadates(V) in relation to biochemistry of vanadium. J. Inorg. Biochem. 25: 51-55, 1985.
28. Djordjevic, C., Vuletic, N., Renslo, M. L., Puryear, B. C., and Alimard, R. Peroxo Heteroligand Vanadates(V). Synthesis, spectrastructure relationships, and stability toward decomposition. Mol. Cell. Biochem., 153: 25-29, 1995.
29. Louie, A. Y., and Meade, T. J. Metal complexes as enzyme inhibitors. Chem. Rev. 99: 2711-2734, 1999.
30. D'Cruz, O. J., Dong, Y., and Uckun, F. M. Spermicidal activity of oxovanadium(IV) complexes of 1,10-phenanthroline, 2,2′-bipyridal, 5′-bromo-2′-hydroxyacetophenone and derivatives in humans. Biol. Reprod., 60: 435-444, 1999.
31. Otieno, T., Bond, M. R., Mokry, L. M., Walter, R. B., and Carrano, C. J. Plasmid DNA cleavage by oxo-bridged vanadium(III) dimers without added co-oxidants or reductants. J. Chem. Soc. Chem. Commun. 37-39, 1996.
32. Auld, D. S. Use of chelation agents to inhibit enzymes. In: J. F. Riordan and B. L. Vallee (eds.), Methods Enzymol., Vol. 158, pp. 110-114. New York: Academic Press, 1988.
33. Sun, Y., Bian, J., Wang, Y., and Jacobs, C. Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound. Oncogene, 14: 385-393, 1997.
34. Kastan, M. B., Canman, C. E., and Leonard, C. J. p53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev., 14: 3-15, 1995.
35. Liebermann, D. A., Hoffman, B., and Steinman, R. A. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene, 11: 199-210, 1995.